Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
29.43
+0.07 (0.24%)
At close: Mar 6, 2026, 4:00 PM EST
29.72
+0.29 (0.99%)
After-hours: Mar 6, 2026, 7:53 PM EST
Celldex Therapeutics Employees
Celldex Therapeutics had 198 employees as of December 31, 2025. The number of employees increased by 12 or 6.45% compared to the previous year.
Employees
198
Change (1Y)
12
Growth (1Y)
6.45%
Revenue / Employee
$7,803
Profits / Employee
-$1,306,854
Market Cap
1.96B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 800 |
| Ascentage Pharma Group International | 605 |
| Syndax Pharmaceuticals | 298 |
| Zymeworks | 263 |
| Soleno Therapeutics | 182 |
| Stoke Therapeutics | 128 |
| Aurinia Pharmaceuticals | 128 |
| Olema Pharmaceuticals | 122 |
CLDX News
- 7 days ago - Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 - GlobeNewsWire
- 9 days ago - Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 10 days ago - Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria - GlobeNewsWire
- 12 days ago - Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile - GlobeNewsWire
- 26 days ago - Celldex to Present at Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - MoneyShow's Best Investment Ideas For 2026: Part 3 - Seeking Alpha
- 3 months ago - Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism - GlobeNewsWire
- 4 months ago - Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer - GlobeNewsWire